Prognosis of lung cancer associated with cystic airspaces: A propensity score matching analysis

医学 肺癌 内科学 匹配(统计) 倾向得分匹配 癌症 病理 肿瘤科
作者
Yingran Shen,Yunfei Zhang,Yanhua Guo,Weitong Li,Yan Huang,Tong Wu,Gening Jiang,Jie Dai
出处
期刊:Lung Cancer [Elsevier]
卷期号:159: 111-116 被引量:23
标识
DOI:10.1016/j.lungcan.2021.07.003
摘要

The association between the morphological characteristics and survival outcome of lung cancer associated with cystic airspaces (LCCAs) is unclear due to rarity of this disease. The current study attempted to compare the survival outcome between LCCAs and non-LCCAs and investigate the correlation between imaging features and prognosis of LCCA.Of 10,835 patients diagnosed with non-small cell lung carcinoma (NSCLC) between January 2015 and December 2016, 123 patients with LCCA were included. The non-LCCA group comprised 3136 patients with primary solitary adenocarcinoma or squamous cell lung cancer. Propensity score matching (PSM) was performed for age, sex, tumor size, tumor stage, and lymph node involvement in a 1:1 ratio between the LCCAs and non-LCCAs, and the correlation between radiological features and recurrence-free survival (RFS) was analyzed.The computed tomography (CT) lesion size was found to be higher in all LCCA subtypes, particularly in Type III (a cystic airspace with a mural nodule) and Type IV (mixed) LCCAs (3.09 and 3.65 cm, respectively), than in non-LCCAs (2 cm) after PSM. Three-year RFS in the LCCA group was higher than in the non-LCCA group (Type I- IV LCCAs: 100%, 84%, 77% and 83%, respectively vs. non-LCCAs: 77%). However, statistically significant difference was only found in comparison between LCCA Type I (thin-walled) and non-LCCA groups (P = 0.026). Type III lung cancer exhibited the worst survival among all four LCCA subtypes.The CT lesion size and pathologic tumor size varied significantly across LCCAs. Type I LCCAs exhibited better survival than non-LCCAs, whereas Type III LCCAs exhibited the worst survival rate among the four LCCA subtypes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
JamesPei应助zzqblue采纳,获得10
刚刚
时尚朋友发布了新的文献求助10
1秒前
zffang完成签到,获得积分10
1秒前
里打动完成签到,获得积分10
2秒前
小蘑菇应助wang采纳,获得10
2秒前
望远镜发布了新的文献求助10
3秒前
李爱国应助熊熊采纳,获得10
3秒前
sw123发布了新的文献求助10
4秒前
4秒前
5秒前
5秒前
淡定完成签到,获得积分20
5秒前
任性诺言应助碧蓝麦片采纳,获得10
6秒前
所所应助刘小文采纳,获得10
6秒前
7秒前
RJ应助巨龙先生采纳,获得10
7秒前
慕青应助moon采纳,获得10
7秒前
淡定发布了新的文献求助10
8秒前
乌鲁鲁发布了新的文献求助10
8秒前
an发布了新的文献求助10
8秒前
勤奋的颦完成签到,获得积分10
9秒前
搜集达人应助早早上岸采纳,获得10
9秒前
shuqi完成签到 ,获得积分10
10秒前
华仔应助Gaoxiang采纳,获得10
10秒前
科研通AI6.1应助独特宛海采纳,获得10
10秒前
10秒前
速速完成签到,获得积分10
11秒前
无物发布了新的文献求助10
11秒前
lg发布了新的文献求助10
11秒前
Cynoto完成签到,获得积分10
11秒前
11秒前
12秒前
扶摇完成签到 ,获得积分10
12秒前
Fishchips发布了新的文献求助10
13秒前
小憨瀚发布了新的文献求助10
14秒前
Beto发布了新的文献求助10
15秒前
咸鱼王的挣扎完成签到,获得积分10
15秒前
研太贤完成签到,获得积分10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 3000
Digital Twins of Advanced Materials Processing 2000
Polymorphism and polytypism in crystals 1000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6041528
求助须知:如何正确求助?哪些是违规求助? 7782399
关于积分的说明 16234950
捐赠科研通 5187607
什么是DOI,文献DOI怎么找? 2775815
邀请新用户注册赠送积分活动 1758984
关于科研通互助平台的介绍 1642493